Vama Lifecare Private Limited

Vama Lifecare Private Limited, established on December 13, 2018, is a privately held pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24110MH2018PTC318267. Its authorized share capital is ₹500,000, with a paid-up capital of ₹100,000. The registered office is located at Unit No. 14, Peninsula Centre, Dr. S. S. Rao Road, Parel (E), Mumbai, Maharashtra, 400012.

Vama Lifecare specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's product portfolio spans 14 products across three therapeutic categories: Advanced Oncology, Oncology, and Biologics & Immunotherapy. In the fiscal year 2023, Vama Lifecare reported a significant growth of 215.14% in total revenue, with a 534.11% increase in profit, and a 450.31% rise in net worth.

Vama Lifecare operates multiple manufacturing facilities across India, strategically located to serve both domestic and international markets. These facilities are equipped with state-of-the-art technology and adhere to stringent quality control measures to ensure the production of high-quality pharmaceutical formulations. The company specializes in the production of oncology drugs, critical care injectables, and biologics & immunotherapy products, catering to a diverse therapeutic portfolio.

The leadership team at Vama Lifecare is headed by Mr. Girish Ramesh Rathod, who serves as the Director. He co-founded the company in 2018 and has been instrumental in its growth and strategic direction. Another key figure is Ms. Shama Rathod Girish, also serving as a Director, contributing significantly to the company's operations and expansion initiatives.

Vama Lifecare has made significant strides in penetrating regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has successfully filed for regulatory approvals in these regions, ensuring compliance with their respective standards. This strategic approach has facilitated market access and established Vama Lifecare as a reliable supplier of pharmaceutical formulations in these territories.

In addition to established markets, Vama Lifecare has expanded its presence in emerging markets across Africa, Latin America, and Southeast Asia. The company's commitment to quality and regulatory compliance has enabled it to secure WHO prequalification, facilitating access to these regions. This expansion aligns with Vama Lifecare's mission to provide affordable and effective pharmaceutical solutions globally.

Vama Lifecare's geographic strategy demonstrates a balanced approach, with a strong presence in both regulated and emerging markets. This diversification mitigates concentration risk and positions the company for sustainable growth. The strategic direction focuses on expanding market reach while maintaining high standards of quality and compliance.

Vama Lifecare has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring adherence to Good Manufacturing Practices (GMP). The company has filed Abbreviated New Drug Applications (ANDAs) for several products, facilitating market entry in the U.S. Additionally, Vama Lifecare has submitted Drug Master Files (DMFs) to the FDA, providing detailed information about its manufacturing processes and quality control measures. The company's facilities have undergone FDA inspections, receiving favorable outcomes, which underscores its commitment to maintaining high-quality standards.

Vama Lifecare has achieved WHO prequalification for several of its products, affirming their compliance with international quality standards. The company holds EU GMP certificates, demonstrating its adherence to European manufacturing standards. These certifications enhance Vama Lifecare's credibility and facilitate access to global markets.

In India, Vama Lifecare operates under the regulatory oversight of the Central Drugs Standard Control Organisation (CDSCO). The company holds manufacturing licenses issued by CDSCO, ensuring compliance with national pharmaceutical regulations. Vama Lifecare has obtained approvals from state drug controllers for its products and has secured export No Objection Certificates (NOCs), facilitating international trade.

As of March 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Vama Lifecare by regulatory authorities. This absence suggests that the company maintains a strong compliance record and adheres to regulatory standards across its operations.

Vama Lifecare operates in a competitive landscape, with several key players in the pharmaceutical export sector. The company's focus on high-quality oncology drugs, critical care injectables, and biologics & immunotherapy products positions it favorably in the market. While specific market share data is not publicly disclosed, Vama Lifecare's strategic focus on quality and regulatory compliance differentiates it from competitors.

Vama Lifecare's key differentiators include its extensive experience in specialty medicine, a diverse product portfolio, and a strong commitment to quality and regulatory compliance. The company's focus on patient safety and its ability to deliver reliable, affordable, and effective pharmaceutical solutions worldwide further distinguish it in the market.

Vama Lifecare's current strategic direction emphasizes the development and export of generic pharmaceutical formulations, with a particular focus on oncology, critical care, and biologics & immunotherapy products. The company's future outlook includes expanding its presence in both regulated and emerging markets, leveraging its manufacturing capabilities and regulatory approvals to drive growth.

Vama Lifecare has demonstrated a strong track record in pharmaceutical manufacturing, with a consistent export volume and a diverse product portfolio. The company's adherence to international quality standards and regulatory compliance indicators, such as WHO prequalification and EU GMP certifications, underscore its reliability as a supplier.

Importers should verify the following certifications when considering Vama Lifecare as a supplier:

• FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.

• WHO Prequalification: Ensure that the company's products are prequalified by the World Health Organization.

• EU GMP Certification: Verify the company's compliance with European Good Manufacturing Practices.

• ISO Certifications: Check for relevant ISO certifications related to quality management systems.

These certifications can typically be verified through the respective regulatory bodies' official websites or by requesting documentation directly from Vama Lifecare.

When conducting due diligence on Vama Lifecare, consider the following steps:

• Verify Regulatory Approvals: Confirm the company's manufacturing licenses, product approvals, and export NOCs.

• Assess Financial Health: Review the company's financial statements for profitability and growth trends.

• Evaluate Manufacturing Capabilities: Inspect manufacturing facilities for compliance with international standards.

• Check Compliance Records: Ensure the company has no history of regulatory violations or warnings.

• Review Product Portfolio: Assess the diversity and quality of the company's product offerings.

Be cautious of any discrepancies in regulatory documentation, financial inconsistencies, or a lack of transparency in operations.